A Study of E7130 in Participants With Solid Tumors

Prior treatment

• Serious concomitant systemic infection requiring medical treatment (including bacterial infection and fungal infection)
• Women of childbearing potential or men of impregnate potential who don't agree that both the participant and his/her partner will use a medically effective method for contraception during the study and after study drug discontinuation (male; 90 days, female; 60 days)
• Known intolerance to the study drug or any of the excipients
• Scheduled for surgery during the study

Other illness

• Medical history of clinically significant cardiovascular impairment
• Participants who test positive for human immunodeficiency virus (HIV antibody)
• Active viral hepatitis (B or C) as demonstrated by positive serology or requiring treatment hepatitis B surface antigen (HBsAg), anti-hepatitis B surface antibody (anti-HBs)/hepatitis B core antibody (HBcAb) and anti-hepatitis C virus (HCV) antibody test.
• Other active malignancy
• Any medical or other condition that in the opinion of the investigator(s) would preclude the participant's participation in the study

Lab values

• Participants whose toxicity of previous treatment has not recovered to Grade 1 or lower (except for alopecia and hemoglobin)

Other

• Effusion requiring drainage
• Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin [ß-hCG] or human chorionic gonadotropin [hCG]).
• Diagnosed with meningeal carcinomatosis
• Participants with brain or subdural metastases are not eligible.

• Participants who have provided voluntary written consent for participation in this clinical study
• Participants to whom the rules for complying with this clinical study have been adequately explained, and who intend to and can comply with these rules
• Participants aged greater than or equal to (>=) 20 years at the time of informed consent
• Participants with adequate function of major organs
• Participants with Performance Status score of 0 to 1 established by the Eastern Cooperative Oncology Group (ECOG)
• Participants who are expected to survive for 3 months or longer after starting administration of the investigational drug
• Washout period required from the end of prior treatment to the first administration of study drug
• Participants who agree to submit blood samples prior and during study treatment for progressive disease (PD) markers.
• Measurable disease meeting the following criteria:
  • At least 1 lesion of >=1.0 centimeter (cm) in the longest diameter for a non-lymph node or >=1.5 cm in the short-axis diameter for a lymph node that is serially measurable according to response evaluation criteria in solid tumours (RECIST) 1.1 using computerized tomography/magnetic resonance imaging (CT/MRI).
  • Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF) ablation must show evidence of progressive disease to be deemed a target lesion.